A top 10 international pharmaceutical company leveraged H1 to identify HCPs seeing diverse patients with a given cardiovascular disease and within a 50 mile radius of the existing trial sites.
The company specifically wanted to increase women and minority participation for clinical trial recruitment across trials. The ideal cohort needed to be 50% women participation to ensure coverage and clinical benefit beyond that of what competitor trials have enrolled across this indication.
They wanted to use the data to try and increase recruitment of diverse patients and roll out target lists to feasibility teams.
Download the case study.